Petros Pharmaceuticals, Inc. Finite-Lived Intangible Assets, Net
Petros Pharmaceuticals, Inc. (PTPI) had Finite-Lived Intangible Assets, Net of $3.20 million as of 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsNet · last filed 2025-03-31
- 2024-12-31: Finite-Lived Intangible Assets, Net $3.20M.
- 2024-09-30: Finite-Lived Intangible Assets, Net $6.83M.
- 2024-06-30: Finite-Lived Intangible Assets, Net $7.54M.
- 2024-03-31: Finite-Lived Intangible Assets, Net $8.26M.
| Period end | Finite-Lived Intangible Assets, Net |
|---|---|
| 2024-12-31 | $3.20M 10-K · filed 2025-03-31 |
| 2024-09-30 | $6.83M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $7.54M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $8.26M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $8.97M 10-K · filed 2025-03-31 |
| 2023-09-30 | $9.77M 10-Q · filed 2023-11-15 |
| 2023-06-30 | $10.60M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $11.42M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $12.24M 10-K · filed 2025-03-31 |
| 2022-09-30 | $13.16M 10-Q/A · filed 2022-11-15 |
| 2022-06-30 | $22.18M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $23.73M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $25.29M 10-K · filed 2024-04-01 |
| 2021-09-30 | $26.98M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $28.71M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $30.43M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $32.16M 10-K · filed 2023-03-31 |
| 2019-12-31 | $38.81M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |